Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of Influenza A Group 1 and Influenza A Group 2 mRNA Chimeric Hemagglutinin Vaccine Candidates Alone and in Combination in Healthy Adults.

NCT07703514 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT07703514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07703514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of Influenza A Group 1 and Influenza A Group 2 mRNA Chimeric Hemagglutinin Vaccine Candidates Alone and in Combination in Healthy Adults.
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 18, 2026
Completion date
April 12, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza